… has an extensive background in RNA modulation and orphan drug discovery and development and is currently in charge of our R&D. Gerard has … in May 2024. Dr. Shannon has had an extensive career in drugdevelopment and pharma. From 2012 until his retirement …
On behalf of all ProQRians, happy Rare Disease Day 2022. Both within ProQR and outside, we join the community in raising awareness and trying to generate change for people worldwide living with a rare disease, their families, and supporters.
… ProQR Appoints David M. Rodman, MD as Chief Development Strategy Officer LEIDEN, the Netherlands, March … Strategy Officer. Dr. Rodman has had a long career in drugdevelopment including leadership roles in translational …
… fibrosis (CF) patients in mid-2017. Investigational new drug (IND) application for QR-110, ProQR’s lead program in … 10 patients. David M. Rodman, MD was appointed as Chief Development Strategy Officer of ProQR, and will lead the … Strategy Officer. Dr. Rodman has had a long career in drugdevelopment including leadership roles in translational …
… held on April 8 - 10 in Monte Carlo, Monaco. World Orphan Drug Congress USA On Thursday, April 26, 2018 at 5:20 pm ET, … companies are ramping up innovation to boost orphan drugdevelopment and patient centricity’ during the World …
… as Senior Corporate Officer, Head of Global Research and Development and Chief Scientific Officer at Santen, a global … With more than 20 years of experience in global drugdevelopment, Dr. Shams has played a significant role in …
… inherited retinal diseases, developing therapies and the development of 3D retinal organoids. Thaddeus (Ted) Drija, MD … and has more than two decades of experience in RNA drugdevelopment from discovery through drug registration, …
